Ocrelizumab

There's Copaxone, which is an injection.

And then there's Ocrevus, which you can kind of do a balancing game on.

But really, ultimately, it's completely up to you.

But I do wish you the absolute best on your journey of trying to conceive.

And then here we are several years later.

And then there was a relapse sprinkled in there, a change of medication sprinkled in there.

And now on Ocrevus, you know, they first said, like, you cannot get pregnant on Ocrevus.

There's a six-month window.

And so what phenobrutinib showed in that clinical trial, which was in primary progressive MS, was that it is not inferior to ocrelizumab, which is currently the only treatment that we have.

or primary progressive MS.

And then when you look at actually the disability curves, starting from 24 weeks, which is about six months, Benabrutinib, the curve actually showed a greater magnitude of a benefit in comparison to Ocrelizumab But again, because the trial was designed as a non-inferiority trial, we can only say clearly that it's not inferior to ocrelizumab.

But again, based on what we know about the drug and that it gets into the central nervous system, it's really encouraging to see these results.

So overall, really exciting because phenobrutinib has differentiated itself from prior BTK inhibitors in that it very clearly has a powerful effect on reducing relapses.

The data arrive while phenobrutinib's application is under FDA priority review for both relapsing and primary progressive MS.

And in progressive MS, Roche's oral candidate was measured against Ocrevus, its own intravenous therapy.

So the benchmark there is a Roche infusion rather than a rival's drug.

Also in MS, TG Therapeutics has released poster data from Enhance, a study of how patients start Briumvi, its approved intravenous ublituximab for relapsing MS.

It also reduced new or enlarging MRI lesions by over seventy percent and demonstrated a positive trend towards slowing disability accumulation.

The clinical trial that tested fenobrutinib for primary progressive MS evaluated fenobrutinib directly against the current standard of care, Ocrevus, and fenobrutinib performed at least as well, showing a twelve percent reduction in the risk of confirmed disability progression.

And this benefit was observed even among trial participants with primary progressive MS who showed no active MRI inflammation.

Now, that's a group that historically hasn't gained much from traditional B-cell-depleting infusions.

And in my head I'm like so the doctor said, oh, it's a lot riskier.

Well, isn't it more riskier to have someone on Ocrevus for 30-odd years at a low-level chemo?

than

spending, yes, 30 days in a hospital being monitored, being sent home.

And by that time I was already pregnant with my first child.

So the third medication, the first medication was Tizabri, the second one, Ocrevus, and the third one was Copaxone that I supposed to inject myself during pregnancy.

And I just couldn't bear the thought of like injecting myself for every single day during pregnancy when that's supposed to be a time where you bond and giving like all it was just unbearable so of

course of course i've got a question for you i've got a question

That low battery warning is exactly what his central nervous system is doing.

But, you know, for you listeners, the charger in this scenario, the Ocrevus infusion, isn't just a simple boost of energy.

No,

not at all.

But why does it knock him down so hard? I mean, if this medicine is supposed to be helping him manage the MS, why does the cure seem to incapacitate him just as much as the disease?

It really comes down to the biological mechanism of the drug.

Ocrevus is a targeted therapy.

Okay.